Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio moves on Thursday, March 12, according to the firm’s daily trade disclosures. The funds increased their stakes in biotech and digital payment companies while cutting positions in select healthcare and semiconductor equipment stocks.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

What Did Wood Buy on March 12?

The largest buy of the day was CRISPR Therapeutics CRSP -2.12% ▼ . ARK purchased 112,815 shares through the ARK Innovation ETF ARKK -3.33% ▼ and the ARK Genomic Revolution ETF ARKG -5.42% ▼ for about $5.63 million, reinforcing Wood’s long-term focus on gene-editing technology.

Another major purchase was PayPay Corp. PAYP +13.50% ▲ . ARK bought 275,000 shares through the ARK Fintech Innovation ETF ARKF -2.89% ▼ , a trade valued at roughly $4.4 million, highlighting the fund’s continued interest in digital payment platforms.

In addition, ARK added 52,075 shares of GeneDx WGS -9.69% ▼ through ARKK and ARKG, worth about $4.43 million. The fund also picked up 18,820 shares of Tempus AI TEM -5.98% ▼ through ARKG for around $991,000.

Here’s What Wood Sold on Thursday

On the sell side, ARK reduced its stake in Teradyne TER -5.09% ▼ , selling 10,919 shares through the ARK Innovation ETF ARKK -3.33% ▼ for about $3.3 million. The move continues a recent trend of trimming the chip-testing equipment maker.

Similarly, ARK scaled back its position in Ionis Pharmaceuticals IONS -3.28% ▼ . The fund sold 43,533 shares through the ARK Genomic Revolution ETF ARKG -5.42% ▼ , a transaction valued at about $3.26 million.

ARK also trimmed 10x Genomics TXG -7.43% ▼ , selling 18,392 shares through ARKK and ARKG, worth roughly $376,000. In addition, the firm reduced its stake in Circle Internet Group CRCL +1.21% ▲ by selling 11,194 shares via ARKK for about $1.26 million.

Wood’s Strategic Portfolio Shuffle

Let’s see how these stocks perform using the TipRanks Stock Comparison Tool.

Currently, analysts rate GeneDx and Ionis Pharmaceuticals as “Strong Buy.” Among the names listed, GeneDx offers the highest upside potential of about 100%. Meanwhile, CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics carry Moderate Buy ratings, while PayPal is rated Hold by analysts.

Disclaimer & DisclosureReport an Issue